| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | spike glycoprotein | ||||
| GTO ID | GTC2698 |
| Trial ID | NCT04900467 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | BNT162b2|COMIRNATY|Tozinameran;mRNA-1273|Elasomeran|Spikevax |
| Location approved | UK, Bahrain, Israel, Canada, US, Rwanda, Serbia, United Arab Emirates, China, Mexico, Kuwait, Singapore, Saudi Arabia, Chile, Switzerland, EU, Ghana, Colombia, Philippines, Indonesia, Australia, Peru, South Korea, New Zealand, Japan, Brazil, Sri Lanka, Vietnam, South Africa, Thailand, Oman, Egypt, Malaysia;UK, Canada, China, Switzerland, Japan, EU, Australia, South Korea, Singapore, US |
| Phase | Not Applicable |
| Recruitment status | Unknown |
| Title | Multicenter, Randomized, Open-label Trial Comparing the Immunological Efficacy of a Vaccine Regimen Combining Two Covid19 mRNA Vaccines (Pfizer-BioNTech and Moderna) With That of a Homologous Vaccination of Each Covid19 mRNA Vaccine: Non-inferiority Trial |
| Year | 2021 |
| Country | France |
| Company sponsor | Assistance Publique - Hôpitaux de Paris |
| Other ID(s) | APHP210605|2021-002174-52 |
| Vector information | |||
|
|||
| Cohort1: Comirnaty | |||||||||
|
|||||||||
| Cohort2: Comirnaty_mRNA-1273 | |||||||||
|
|||||||||
| Cohort3: mRNA-1273 | |||||||||
|
|||||||||